Debt Collection Enters a New Era Powered by Vodex's Voice AI Agents
BENGALURU, India, June 18, 2025 /CNW/ -- Vodex, a voice AI startup gaining steady traction in the U.S. collections space, has built a platform specifically designed for compliance-heavy outreach. As rising delinquency, leaner call-center rosters, and stricter federal oversight reshape the landscape, efficiency has become a must-hit metric for debt-collection leaders. Many agencies are now implementing AI-powered voice agents that can contact thousands of consumers an hour while staying within FDCPA and TCPA rules. By automating Tier-1 dials, these agents increase Right Party Contact (RPC) rates and free up human collectors for higher-value negotiations.
Though long-discussed in customer support, AI's role in the high-stakes, regulated, and sensitive collections space is finally evolving and Vodex is helping lead that shift.
Filling in the Tier-1 Gap
First-touch or attempt calls significantly consume an agent's time. Vodex's voice agents fill this gap and help scale with efficiency. Integrated with popular CRMs and skip tracing tools, the agents:
Place and receive calls in real time
Verify consumer identity
Present repayment or hardship options
Log every utterance for ISO 27001, SOC 2, and HIPAA-aligned audits
In one recent use case, a third-party agency reported a 7x improvement in connect rates and a 3x rise in recovery after switching a portion of its Tier-1 calls to AI voice agents.
Where firms are using AI First
Voice agents are now being used not just for recoveries, but also for follow-ups, payment reminders, and verifications across high-volume sectors. Use cases include:
Healthcare RCM: Automated reminders for self-pay patients
Auto Finance: Outbound calls to reduce delinquency
Insurance: Policy renewal and missed premium alerts
BNPL: Instalment recovery follow-ups
Telecom & Utilities: High-frequency billing and service alerts
When a call becomes complex, the bot warm-transfers to a live agent, unlike traditional bots on pre-recorded IVR systems. So, the staff can spend time on Tier-2 dispute resolution rather than voicemail loops. This works especially well for high-compliance scenarios like healthcare collections or buy-now-pay-later (BNPL) follow-ups.
The company has quietly expanded into healthcare, auto finance, telecom, and consumer lending, serving both first-party early-out and third-party recovery programs.
A Compliance-Centric Approach
The platform also integrates with CRM systems and skip tracing tools, allowing for more precise and timely outreach. They also create an audit trail that is ISO 27001, SOC 2, and HIPAA aligned. And this is what sets Vodex apart from the rest, according to several analysts. In a regulatory environment where even minor missteps can lead to legal exposure, this is not a minor detail.
The Quiet Advance of Voice AI
While many AI tools in the market are focused on chat or email, Vodex is part of a newer wave that sees voice as the next battleground, especially in industries where live conversation still drives major impact.
Vodex isn't alone in this space, but its traction in regulated sectors and its technical emphasis on real-time, respectful dialogue suggest a thoughtful approach. As more agencies explore AI's role in augmenting recovery efforts, it may not be long before voice agents become as standard as dialers once were.
"The debt collection space isn't just ready for AI, it's asking for it, AI agents will do what traditional methods can't: engage debtors at scale, stay compliant by design, and improve recovery outcomes with every call," said Anshul Shrivastava, Co-founder & CEO of Vodex.ai.
Part of a Larger Trend
Voice AI, while still in early stages of adoption, is seeing increased acceptance in markets such as the U.S. particularly in pre-sales and collections. With its focus on conversational AI for phone-based interactions.
Founded in 2022, Vodex operates in a growing niche that sits at the intersection of AI, compliance tech, and debt recovery infrastructure. The firm is currently expanding its presence in North America and plans to partner with BPOs and collection firms looking to digitize their recovery workflows.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
NEW YORK, /CNW/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS). A unique RNA splice variant of the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona ("UAB") including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene and gene-engineered cell therapies. The human alpha-Klotho gene is located in cells found throughout the human body. It is a five exon gene that produces two protein isoforms: a full-length protein found mainly in cells of the kidney called membrane-bound Klotho (or m-KL), which controls phosphate homeostasis, and a much smaller protein isoform called secreted alpha-Klotho (or s-KL). The s-KL RNA splice variant is found mainly in the brain and spinal cord neurons; the variant protein is neuroprotective by minimizing both oxidative stress and neuroinflammation. Animal studies supported by the Company over the past two years in mouse and non-human primate models of rapid aging, in models of human Alzheimer's disease, and in models of ALS have shown that over-expression and amplification of the tissue levels of s-KL using a gene therapy approach result in highly favorable therapeutic outcomes in every model tested. These results have been published in peer-reviewed scientific journals and now support the transition of KLTO-202 into the clinical development stage. The Company expects that it will take approximately eight months to complete process development and manufacturing of KLTO-202, and about four to six months to conduct meetings with FDA, complete all FDA-mandated animal safety studies, file an investigational new drug application (IND), train and prepare clinical sites where the Phase I/II studies can be conducted, and then begin the single-dose gene therapy studies in ALS patients by the third quarter of next year. The Company will work with contract research organizations (CROs) to facilitate all activities including manufacturing and clinical trials without the need to hire several dozen staff members, which would significantly increase our operating overhead. Dr. Joseph Sinkule, the Company's CEO and founder commented: "With our recent fundraising success, we're moving forward with manufacturing the s-KL transgene DNA for KLTO-202. We've identified a more efficient method of producing the AAV vector to deliver the s-KL gene directly to motor neurons—the cells most affected by ALS. Our goal is to increase local s-KL protein levels to protect these neurons from the damage that leads to voluntary and involuntary muscle paralysis and ultimately death." ALS typically progresses rapidly, with most patients losing mobility, respiratory function, and life within just 2–3 years of diagnosis. About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO [email protected] Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Globe and Mail
2 hours ago
- Globe and Mail
Imagen Network Taps Solana to Roll Out AI-Powered Social Features for Decentralized Growth
Fast, scalable AI social modules launch on Solana to expand creator-led communities and multichain identity tools. Seattle, Washington--(Newsfile Corp. - June 30, 2025) - Imagen Network, the decentralized AI-powered social platform, has announced the launch of its first AI-driven social modules on the Solana blockchain. This expansion brings fast, scalable engagement tools to the network—enabling communities to build smarter, more personalized social spaces that operate across chains. Expanding decentralized social tools through Solana-powered AI modules. To view an enhanced version of this graphic, please visit: With Solana's high-speed infrastructure, Imagen is deploying tools like real-time AI moderation, sentiment-based feed customization, and automated content assistants to help users and creators shape their communities. These tools are lightweight, modular, and seamlessly integrate with Imagen's node-based social architecture. The launch also introduces multichain identity syncing and governance tokens tailored for Solana-native communities. Users can now maintain consistent reputations, personalized feeds, and profile continuity across Ethereum, BNB Chain, and Solana—reinforcing Imagen's commitment to accessible, borderless, user-owned social networking. This rollout follows a wave of major development milestones, including Imagen's MEXC listing, cross-chain moderation layers, and substantial investment backing. With Solana integration now live, Imagen continues its mission to deliver intelligent, decentralized social infrastructure at global scale. About Imagen Network Imagen Network is a decentralized social platform that blends AI content generation with blockchain infrastructure to give users creative control and data ownership. Through tools like adaptive filters and tokenized engagement, Imagen fosters a new paradigm of secure, expressive, and community-driven networking. Media Contact Dorothy Marley KaJ Labs +1 707-622-6168 media@ Social Media Twitter Instagram
Globe and Mail
11 hours ago
- Globe and Mail
Which "Magnificent Seven" Stock Makes the Best Buy for the Second Half?
A group of technology stocks, known as the "Magnificent Seven" -- a nod to the 1960 Western -- led stock market gains last year and has started to rebound in recent times. Which one makes the best buy for the second half? The answer to that question is Nvidia (NASDAQ: NVDA), even though the stock has already climbed 800% over the past three years. Let's find out why this top artificial intelligence (AI) stock may still be in the early days of its growth story. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Nvidia's key position in AI Nvidia has played a key role since the first days of the AI boom, and this is because it designs the crucial element that makes AI work: chips. They're known as graphics processing units (GPUs), and they power the fundamental step of training AI models, a process that allows those models to then handle complex tasks and solve real-world problems. So, without these chips, we wouldn't have AI. This helped Nvidia's revenue take off a few years ago, as you can see in the chart below. NVDA Revenue (Annual) data by YCharts. In Nvidia's earlier days, it primarily served the video gaming market, which resulted in progressive growth, but revenue levels were a far cry from today's AI-driven revenue. This is because companies realize the potential of this technology to save them time and money and even help them develop game-changing products and services, so they're pouring investment into AI. And Nvidia, as the leading chip designer, is benefiting. This potential is further illustrated by forecasts calling for the AI market to reach into the trillions of dollars in a few years from now. Importantly, Nvidia isn't just about GPUs. The company has built an AI empire, creating software and networking tools, and it even aims to power the humanoid robots of tomorrow. This expansion is key to Nvidia's growth because it enables the company to benefit from every stage of AI development -- not just the early days of infrastructure ramp-up. Nvidia's annual innovation Meanwhile, Nvidia has also put the focus on innovation to ensure it stays ahead of its rivals. It has pledged to update its chips yearly and has already offered investors visibility into planned launches over the coming three years. Though rivals are carving out market share -- for example, Advanced Micro Devices recently reported a 57% increase in data center quarterly revenue -- Nvidia's innovation should keep it in the top spot. The enormous demand for AI means that others, like AMD, can succeed without truly encroaching on Nvidia's territory. The biggest disappointment for Nvidia and investors at this point (and possibly into the future) is the situation concerning exports to China. The U.S. has blocked chip exports, cutting Nvidia out of the market that represented 13% of its revenue last year. This isn't a non-event, and if the situation remains as is, it limits Nvidia's growth opportunities to some degree. The good news is that Nvidia makes most of its revenue in the U.S. and a great deal in other locations as well, so the export situation doesn't necessarily translate to slow growth for this chip giant. Why buy Nvidia over other Magnificent Seven players? All this sounds positive, but why is Nvidia the best Magnificent Seven buy for the second half? Nvidia remains the best overall AI bet due to its deep presence across every stage of the technology's growth. The world's biggest tech companies turn to Nvidia to power their platforms, and that's unlikely to change, as these customers aim to use the fastest processors available -- and those are likely to have the name Nvidia on them well into the future. Nvidia will accompany these customers as they deploy AI agents within their businesses or develop humanoid robots down the road. At the same time, Nvidia's valuation leaves the stock plenty of room to run. Though it's inched higher in recent weeks, it still trades significantly lower than it did just a few months ago, at 36 times forward earnings estimates compared to more than 50 times. All these elements, from Nvidia's presence across AI to its price today, support my prediction that this stock will roar higher in the second half and over the long run, too. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
